Cancer Advisor

Abstract Background: Stage 4 prostate cancer has a 5-year survival rate of 37% with standard of care (SOC, e.g., androgen deprivation therapy [ADT], chemotherapy, Lu-177-PSMA-617). An optimized intervention combining repurposed drugs, supplements, diet/lifestyle, hyperthermia, and SOC components may improve outcomes. Methods : We simulated a double-blind RCT with 1,000 patients (500 per arm) with non-BRCA-mutated stage 4 prostate cancer (70% mHSPC, 30% mCRPC), comparing an integrative multimodal intervention arm (ivermectin 1.0–1.5 mg/kg/day (cycled 3 weeks on/1 off), mebendazole 500–1,500 mg/day (titrated), metformin 1,700 mg/day, vitamin C 1 g/kg IV 3 times/week, vitamin D 5,000 IU/day, curcumin 1,000 mg/day, low-glycemic Mediterranean diet, exercise, MBSR, hyperthermia [modulated electro-hyperthermia at 42°C for 60 minutes, 2–3 times weekly], plus ADT/Lu-177-PSMA-617) to a placebo arm with SOC. Primary endpoint was overall survival (OS); secondary endpoints included progression-fre...

Abstract Background: Metastatic castration‑resistant prostate cancer (mCRPC) remains incurable despite modern multimodal therapy including androgen deprivation therapy (ADT) and PSMA‑targeted radioligand therapy. Repurposed antiparasitic agents such as ivermectin, mebendazole, and fenbendazole have attracted interest for potential anticancer effects based on preclinical mechanisms and anecdotal clinical reports. Additionally, an in silico simulated randomized trial has proposed a comprehensive multimodal integrative regimen combining repurposed drugs with diet, supplements, and conventional therapy. Methods: This narrative review synthesizes clinical evidence for standard therapies in advanced prostate cancer and evaluates the available preclinical literature on repurposed antiparasitics. It also integrates data from large case report compilations and in silico simulations to illustrate the current landscape and highlight critical limitations. Results: ADT and ^177Lu‑PSMA‑617 radiol...

Introduction: A New Era in Cancer Care Cancer treatment is evolving faster than ever. From cutting-edge immunotherapies to AI-driven diagnostics, the discoveries of 2025–2026 are reshaping how clinicians detect, monitor, and treat malignancies. These breakthroughs offer hope for longer survival, improved quality of life, and personalized therapies tailored to each patient. Credit:  Statista 1. Immunotherapy: Expanding Beyond Checkpoints Immune checkpoint inhibitors (like pembrolizumab and nivolumab) remain foundational, while CAR‑T therapies, bispecific antibodies, and tumor-infiltrating lymphocytes (TILs) expand treatment options for previously resistant solid tumors. Key Highlights: CAR‑T therapy demonstrates survival benefits in advanced gastric and gastroesophageal junction cancers — a first for solid tumors. Bispecific and dual checkpoint agents provide deeper, more durable responses in early trials. Note: These therapies carry potential risks, including cytokine release syn...

Introduction Facing a cancer diagnosis can feel like navigating an endless maze with no clear direction. The overwhelming emotions and confusion that accompany such news are shared by many. While conventional cancer treatments like chemotherapy and radiation therapy have a role to play, there’s a growing interest in alternative therapies that can complement or even replace traditional methods. Did you know that many alternative cancer treatments have been explored, offering new hope to those affected by cancer? The use of complementary and alternative medicine is becoming more prevalent as patients seek options beyond conventional medical treatments. Alternative medicine includes therapies used outside of standard medical practices, offering different approaches to treat cancer. Integrative medicine combines both conventional and alternative treatments, aiming to improve outcomes and enhance quality of life. Diverse cancer hallmarks targeted by repurposed non-oncology drugs. This figu...